116 related articles for article (PubMed ID: 15997843)
1. Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats.
Hao X; Cheng G; Yu JE; He Y; An F; Sun J; Cui F
Pharmazie; 2005 Jun; 60(6):477-8. PubMed ID: 15997843
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
Xing JF; You HS; Dong YL; Lu J; Chen SY; Zhu HF; Dong Q; Wang MY; Dong WH
Acta Pharmacol Sin; 2011 May; 32(5):655-63. PubMed ID: 21516133
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats.
Liu XB; Ye JX; Quan LH; Liu CY; Deng XL; Yang M; Liao YH
Eur J Pharm Biopharm; 2008 Nov; 70(3):845-52. PubMed ID: 18675905
[TBL] [Abstract][Full Text] [Related]
4. Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics.
Hao X; Cheng G; Sun J; Zou M; Yu J; Zhang S; Cui F
J Pharm Biomed Anal; 2005 Jun; 38(2):360-3. PubMed ID: 15925232
[TBL] [Abstract][Full Text] [Related]
5. Sustained release and enhanced bioavailability of injectable scutellarin-loaded bovine serum albumin nanoparticles.
Wei Y; Li L; Xi Y; Qian S; Gao Y; Zhang J
Int J Pharm; 2014 Dec; 476(1-2):142-8. PubMed ID: 25269007
[TBL] [Abstract][Full Text] [Related]
6. Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite.
Gao C; Chen X; Zhong D
Drug Metab Dispos; 2011 Nov; 39(11):2034-44. PubMed ID: 21810967
[TBL] [Abstract][Full Text] [Related]
7. Two major urinary metabolites of scutellarin in rats.
Qiu F; Xia H; Zhang T; Di X; Qu G; Yao X
Planta Med; 2007 Apr; 73(4):363-5. PubMed ID: 17354170
[TBL] [Abstract][Full Text] [Related]
8. Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
Cao F; Zhang H; Guo J; Ping Q
Pharmazie; 2008 Jan; 63(1):75-80. PubMed ID: 18271309
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Wang J; Tan J; Luo J; Huang P; Zhou W; Chen L; Long L; Zhang LM; Zhu B; Yang L; Deng DY
J Nanobiotechnology; 2017 Mar; 15(1):18. PubMed ID: 28249594
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic and tissue distribution study of scutellarin in rats].
You HS; Dong YL; Xing JF; Zhang CL; Wang MY
Zhongguo Zhong Yao Za Zhi; 2007 Aug; 32(16):1688-92. PubMed ID: 18027669
[TBL] [Abstract][Full Text] [Related]
11. Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry.
Liu Q; Shi Y; Wang Y; Lu J; Cong W; Luo G; Wang Y
Talanta; 2009 Nov; 80(1):84-91. PubMed ID: 19782195
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.
Huang JM; Weng WY; Huang XB; Ji YH; Chen E
Eur J Drug Metab Pharmacokinet; 2005; 30(3):165-70. PubMed ID: 16250252
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of scutellarin and its derivant scutellarin ethyl ester in rats].
Zhu LW; Liu XQ; Feng J; Gao HM; Yi H; Wang ZM; Meng QJ
Zhongguo Zhong Yao Za Zhi; 2013 Oct; 38(19):3373-7. PubMed ID: 24422411
[TBL] [Abstract][Full Text] [Related]
14. Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats.
Cai Y; Anavy ND; Chow HH
Drug Metab Dispos; 2002 Nov; 30(11):1246-9. PubMed ID: 12386131
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.
Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S
Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567
[TBL] [Abstract][Full Text] [Related]
16. [Effect of pravastatin on transportation of scutellarin in mouse liver and its mechanism].
Liu JM; Xiong YQ
Yao Xue Xue Bao; 2011 Mar; 46(3):269-73. PubMed ID: 21626779
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between scutellarin and valsartan in rats.
Cui MY; Tian CC; Ju AX; Zhang CT; Li QH
Yao Xue Xue Bao; 2013 Apr; 48(4):541-6. PubMed ID: 23833943
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of brain-targeted trendence of scutellarin nasal administration].
Shi S; Wu J; Dai W; Li C; Ge W
Zhongguo Zhong Yao Za Zhi; 2010 Sep; 35(18):2453-6. PubMed ID: 21141499
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics and metabolites of scutellarin in normal and model rats].
Gao HM; Wang ZM; Tian J
Yao Xue Xue Bao; 2005 Nov; 40(11):1024-7. PubMed ID: 16499088
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
